Gilead is advancing a differentiated Inflammation/Immunology portfolio across allergic diseases, rheumatologic diseases, inflammatory bowel disease, hepatology-related inflammatory conditions, and other autoimmune diseases. The portfolio includes internal programs, partnered assets, and collaboration-based development efforts spanning multiple stages of clinical development, from pre-IND through Phase 3.
The Vice President, Clinical Development – Inflammation is the senior clinical development leader responsible for defining strategy, setting priorities, driving execution, and providing integrated portfolio leadership across Th2-mediated allergic diseases, rheumatology, and B-cell–mediated autoimmune disease.
This leader will oversee a portfolio spanning multiple assets, indications, development stages, and external collaborations, partnering with internal functions and alliance partners to ensure clinical strategies are scientifically rigorous, operationally feasible, regulatory-aligned, and integrated with broader portfolio objectives.
The VP will lead clinical development leaders and matrixed cross-functional teams, set portfolio priorities, manage development risks, support governance decisions, and ensure high-quality execution across programs.